Board of Directors
Bard Geesaman, M.D., Ph.D.
Bard Geesaman, M.D., Ph.D., has been affiliated with MPM and associated portfolio companies since 2002. With broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel, Bard is a Managing Director of MPM’s Oncology Impact Fund (OIF) and serves as Chief Compliance Officer (CCO).
Prior to MPM, Bard founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Bard joined Centagenetix, an MPM-founded company exploring the genetics of successful aging.
In 2006, Bard joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan. Bard is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Bard is passionate about innovation in health care, and in 2008 took a two year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation.
He received a BS in neuroscience from UC Berkeley followed by concurrent degrees from Harvard Medical School and the Massachusetts Institute of Technology., with his PhD work focused on systems and computational neurobiology. Bard finished his medical training by completing a three-year medical residency at Massachusetts General Hospital.
As a Partner on the Private Transactions team at Deerfield, Leslie works with a variety of healthcare services, healthcare information technology and medical device companies that are both current and potential investment partners. Before joining Deerfield in 2005, Leslie was co-manager of an ING branded healthcare hedge fund she launched in 2000. Prior to that she spent 11 years in the investment banking, high yield research and equity research departments at Furman Selz and ING, where she focused exclusively on companies in the healthcare arena. In these roles Leslie developed wide ranging experience in executing M&A transactions, structuring debt and equity financings for both public and private companies and analyzing company potential through the lens of public investors. She also spent two years as a member of the national healthcare consulting practice of Price Waterhouse. Leslie graduated with High Honors from Wesleyan University, and she earned her M.B.A. from the University of Chicago. She currently serves on the Board of Directors of five Deerfield portfolio companies.
Morana Jovan-Embiricos, PhD
Dr. Jovan-Embiricos is the founder of F2 Ventures. She has extensive experience in both the public and private biotechnology equity markets through a series of funds launched at F2 since 2003. She also successfully managed a biotech allocation for one of the largest hedge funds in the USA. Prior to F2, Dr. Jovan-Embiricos was a Partner with MPM Capital working both on the investment side and directly with portfolio companies to help them attain critical business development milestones and securing appropriate exits either through trade sale or an IPO. She also led life sciences activities at Banque Syz & Co in Geneva, launching one of the first long only biotech funds in Switzerland. Dr. Jovan-Embiricos is also a member of the Board of Damon Runyon Cancer Research Foundation. She holds an Executive Business Program from Stanford-National University of Singapore and was a post-doctoral fellow at Harvard University having worked on protein un-caging in the Department of Developmental Biology. She received her PhD in Biophysical Chemistry from the University of Cambridge.
Gadi Lachman previously held leadership positions at TriZetto, American Well and Eliza. He was also at Lehman Brothers and was an Officer in Israeli Special Forces. Gadi earned his MBA at Harvard Business School, and his LLB in law and B.C. in accounting from Tel-Aviv University.
Jeff Margolis is widely recognized as a healthcare IT entrepreneur and innovator based on his 30-year track record of successfully applying technologies to address the complex problems facing the healthcare industry. Leveraging his deep systematic understanding of healthcare and groundbreaking architectural and integration methodologies, Jeff has built some of the nation’s largest and most innovative healthcare technology and service organizations. Jeff is currently Chairman and CEO of Welltok, Inc., where he is driving the transformation of our current sickcare system to one of optimized health. Prior to Welltok, Jeff founded TriZetto, the first industry vertical SaaS enterprise solution, and originated the concept of Integrated Healthcare Management. During his tenure as Chairman and CEO, Jeff led TriZetto through a successful IPO and $1.4B private equity buyout. Jeff currently serves as a member of the board of directors for Quality Systems, Inc. (NASDAQ:QSII), Alignment Healthcare and TriNetX. Jeff also serves the national and local communities on the boards of several prominent non-profit and for profit organizations, including Hoag Hospital in Newport Beach and the University of California at Irvine Center for Digital Transformation. As a health futurist and visionary, Jeff is a frequent speaker, guest lecturer and author of two books, including The Healthcare Cure. Jeff is an alumnus of the University of Illinois and holds certified public accountant certificates in Colorado and Illinois.
Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.